Sinew Pharma has been granted 49 patents globally, and there are 40 pending applications in prosecution.  The patents for the SNP-8 series granted in the US or other advanced medical countries are expected to expire in November 2033 and we continue to file new indication patents which are expected to expire in February 2039 after patent approval. The patents for the SNP-6 series are expected to expire in September 2036, and we plan to apply for next-generation patents to prolong the term of the product life cycle.